Sage Journals: Discover world-class research

Abstract

Objective. To determine the incidence of stress-related mucosal bleeding (SRMB) in a critically ill oncology population receiving stress ulcer prophylaxis (SUP) with either a histamine-2 receptor antagonist (H2RA) or proton pump inhibitor (PPI). Design. Single-center, prospective, observational study.

Setting. Fifty-two bed medical-surgical intensive care unit of an academic oncology institution. Patients. A convenience sample of 100 medical and surgical critically ill oncology patients who received intensive care for more than 24 hours and at least one dose of a H2RA or PPI for prevention of SRMB.

Interventions. None.

Measurements and Main Results. Patients were followed throughout their intensive care unit stay for the development of an overt and/or clinically significant gastrointestinal (GI) bleed. More patients received a PPI (n = 81) in contrast to a H2RA (n = 19) for SUP. Overall, 94 patients (94%) had at least one risk factor for a SRMB with four patients (4%) experiencing an event (overt bleed, n=3; clinically significant bleed, n =1). All cases of GI bleeding occurred in patients receiving a PPI. No ICU deaths were considered directly related to a GI bleed.

Conclusions. The incidence of SRMB among high-risk critically ill oncology patients receiving SUP appears low; further, large-scale trials are needed to confirm this finding. J Oncol Pharm Practice (2009) 15: 9—16.

Keywords

critical illness intensive care units neoplasms gastrointestinal hemorrhage histamine H2 antagonists proton pump inhibitors

Get full access to this article

View all access options for this article.

References

ASHP Commission on Therapeutics. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. Am J Health Syst Pharm 1999; 56: 347-79.

MacLaren R. A review of stress ulcer prophylaxis. J Pharm Pract 2002; 15: 147-57.

Mutlu GM , Mutlu EA , Factor P. GI complications in patients receiving mechanical ventilation. Chest 2001; 119: 1222-41.

Schuster DP , Rowley H. , Feinstein S. et al. Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med 1984; 76: 623-30.

Cook DJ , Fuller HD , Guyatt GH et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994; 330: 377-81.

Cook D. , Guyatt G. , Marshall J. et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation . N Engl J Med 1998; 338: 791-7.

Cook DJ , Griffith LE , Walter SD et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients . Crit Care 2001; 5: 368-75.

Ben-Menachem T. , Fogel R. , Patel RV et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit: a randomized, controlled, single-blind study. Ann Intern Med 1994; 121: 568-75.

Daley RJ , Rebuck JA , Welage LS et al. Prevention of stress ulceration: current trends in critical care. Crit Care Med 2004; 32: 2008-13.

10.

Conrad SA , Gabrielli A. , Margolis B. et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005; 33: 760-5.

11.

Dellinger RP , Carlet JM , Masur H. et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004 ; 32: 858-73.

12.

Levy MJ , Seelig CB , Robinson NJ et al. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis . Dig Dis Sci 1997; 42: 1255-9.

13.

Kantorova I. , Svoboda P. , Scheer P. et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterol 2004 ; 51: 757-61.

14.

Schell HW The risk of adrenal corticosteroid therapy in far-advanced cancer. Am J Med Sci 1966; 252: 641-9.

15.

Conn HO , Blitzer BL Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976; 294: 473-9.

16.

Ottonello GA , Primavera A. Gastrointestinal complication of high-dose corticosteroid therapy in acute cerebrovascular patients. Stroke 1979; 10: 208-10.

17.

Messer J. , Reitman D. , Sacks HS et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309: 21-4.

18.

Estruch R. , Pedrol E. , Castells A. et al. Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward. Scand J Gastroenterol 1991; 26: 819-26.

19.

Piper JM , Ray WA , Daugherty JR et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991 ; 114: 735-40.

20.

de Kaski MC , Levi S. , Rentsch R. et al. Steroid ulcers. BMJ 1992; 304: 1443-4.

21.

Dayton MT , Kleckner SC , Brown DK Peptic ulcer perforation associated with steroid use. Arch Surg 1987; 122: 376-80.

22.

Raptis A. , Mavroudis D. , Suffredini AF et al. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant 1999; 24: 879-83.

23.

Lewis ID , DeFor T. , Weisdorf DJ Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy. Bone Marrow Transplant 2000; 26: 539-43.

24.

Afessa B. , Tefferi A. , Litzow MR et al. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002; 166: 1364-68.

25.

Merki HS , Wilder-Smith CH

Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?

Gastroenterology 1994; 106: 60-4.

26.

Labenz J. , Peitz U. , Leusing C. et al. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomized controlled trial. Gut 1997; 40: 36-41.

27.

Netzer P. , Gaia C. , Sandoz M. et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999; 94: 351-7.

28.

Forrest JA , Finlayson ND , Shearman DJ Endoscopy in gastrointestinal bleeding. Lancet 1994; 2: 394-7.

29.

Lin HJ , Lo WC , Lee FY et al. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Ann Intern Med 1998; 158: 54-8.

30.

Lau JY , Sung JJ , Lee KK et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343: 310-6.

31.

Sung JJ , Chan FK , Lau JY et al. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: a randomized comparison. Ann Intern Med 2003 ; 139: 237-43.

Stress-related mucosal bleeding in critically ill oncology patients

Abstract

Keywords

Get full access to this article

References